HC Wainwright Issues Pessimistic Forecast for COYA Earnings

Coya Therapeutics, Inc. (NASDAQ:COYA) – Investment analysts at HC Wainwright decreased their Q1 2026 earnings per share (EPS) estimates for Coya Therapeutics in a research note issued to investors on Monday, March 23rd. HC Wainwright analyst R. Selvaraju now forecasts that the company will post earnings of ($0.39) per share for the quarter, down from their previous forecast of ($0.33). HC Wainwright currently has a “Buy” rating and a $18.00 price objective on the stock. The consensus estimate for Coya Therapeutics’ current full-year earnings is ($1.15) per share. HC Wainwright also issued estimates for Coya Therapeutics’ Q2 2026 earnings at ($0.39) EPS, Q3 2026 earnings at ($0.41) EPS, Q4 2026 earnings at ($0.43) EPS and FY2026 earnings at ($1.64) EPS.

A number of other analysts have also weighed in on the company. D. Boral Capital reiterated a “buy” rating and issued a $15.00 target price on shares of Coya Therapeutics in a research note on Monday, March 16th. Weiss Ratings reissued a “sell (d-)” rating on shares of Coya Therapeutics in a research note on Wednesday, January 21st. Wall Street Zen cut shares of Coya Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday. Finally, Chardan Capital reaffirmed a “buy” rating and issued a $14.00 price target on shares of Coya Therapeutics in a research note on Monday, March 16th. Five equities research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $16.00.

Coya Therapeutics Stock Performance

Shares of COYA stock opened at $4.15 on Wednesday. The stock has a 50 day moving average price of $4.67 and a 200 day moving average price of $5.48. Coya Therapeutics has a 52-week low of $3.94 and a 52-week high of $7.75. The firm has a market capitalization of $97.36 million, a P/E ratio of -3.27 and a beta of 0.23.

Coya Therapeutics (NASDAQ:COYA) last released its earnings results on Monday, March 16th. The company reported ($0.34) EPS for the quarter, missing analysts’ consensus estimates of ($0.08) by ($0.26). Coya Therapeutics had a negative net margin of 267.13% and a negative return on equity of 62.76%. The business had revenue of $3.96 million for the quarter, compared to the consensus estimate of $1.93 million.

Hedge Funds Weigh In On Coya Therapeutics

Several institutional investors have recently made changes to their positions in the company. JPMorgan Chase & Co. purchased a new position in Coya Therapeutics during the 3rd quarter valued at about $28,000. CIBC Private Wealth Group LLC purchased a new position in Coya Therapeutics in the fourth quarter worth $47,000. Occudo Quantitative Strategies LP purchased a new position in Coya Therapeutics during the 4th quarter worth $66,000. Lantern Wealth Advisors LLC acquired a new position in shares of Coya Therapeutics during the third quarter valued at about $66,000. Finally, Oppenheimer & Co. Inc. acquired a new position in Coya Therapeutics during the 4th quarter valued at approximately $81,000. Hedge funds and other institutional investors own 39.75% of the company’s stock.

Coya Therapeutics News Summary

Here are the key news stories impacting Coya Therapeutics this week:

• Positive Sentiment: H.C. Wainwright reiterated a Buy rating and kept a high $18.00 price target, and its analyst published FY2027 and quarterly EPS forecasts that anticipate continued investment in the pipeline — this bullish research likely supports investor interest in COYA’s long‑term upside. TipRanks: H.C. Wainwright reiterates Buy
• Neutral Sentiment: Multiple reports show a “large increase” in short interest for March, but the published short-interest totals are zero (and days-to-cover ratios are 0.0), indicating the short-interest data is anomalous/likely erroneous — not a clear driver of price action today.
• Negative Sentiment: Recent quarterly results (reported March 16) showed an EPS miss (reported -$0.34 vs. consensus -$0.08) and continued negative margins and ROE, which keep near-term fundamentals pressured and can blunt enthusiasm from bullish analyst notes.
• Negative Sentiment: Technical and trading context is unfavorable: the stock is below its 50‑day ($4.68) and 200‑day ($5.50) moving averages and near its 52‑week low, and intraday volume is below average — factors that can contribute to downward price pressure despite positive coverage.

About Coya Therapeutics

Coya Therapeutics, Inc (NASDAQ: COYA) is a clinical‐stage biotechnology company focused on the discovery and development of first‐in‐class therapeutics for fibrotic diseases and cancer. The company’s scientific approach centers on targeting UNC-45A, a molecular chaperone implicated in the regulation of cell motility, proliferation and extracellular matrix deposition. By modulating the activity of UNC-45A, Coya aims to address underlying mechanisms of tissue fibrosis and tumor progression that currently lack effective treatments.

Coya’s pipeline is anchored by two lead programs: COY-001, a small‐molecule inhibitor in preclinical development for fibrotic disorders such as idiopathic pulmonary fibrosis and systemic sclerosis, and COY-002, which is being advanced toward the clinic for certain solid tumors.